GET DAILY SIGNALSTactile Medical (TCMD) Shows Resilient Lymphedema Growth in Q3 Despite Margin Pressure
Key Takeaways
- Third quarter 2026 revenue rose 7% year over year to $91.9 million, led by a 13% increase in lymphedema products to $81.8 million.
- Airway clearance (AffloVest) revenue fell 25% to $10.0 million amid a durable medical equipment (DME) inventory transition tied to a new product launch.
- GAAP net income declined to $7.2 million, or $0.31 per diluted share, from $8.2 million, or $0.36, a year earlier.
- Gross margin expanded to roughly 77%, marking a 12th consecutive quarter of improvement, while adjusted EBITDA held roughly flat at $14.3 million.
- Management reiterated its full-year 2026 revenue outlook of $360 million to $366 million and raised its adjusted EBITDA guidance to $50 million to $52 million.
Putting the Quarter in Perspective
Tactile Systems Technology, Inc., operating as TCMD, develops at-home therapies for chronic vascular and lymphatic conditions. Its third quarter 2026 results provide a useful look at whether the core lymphedema business can sustain its momentum while the smaller airway clearance segment navigates a distribution shift. The report also highlights how increased investments in sales and technology are affecting profitability. After earlier strength in 2025, expectations were high around execution and cost control.
Breaking Down the Reported Results
Total revenue for the quarter ended September 30, 2026, rose 7% year over year to $91.9 million, slightly below consensus estimates near $91.99 million. Lymphedema revenue, covering Flexitouch, Nimble, and LymphaTech, increased 13% to $81.8 million for its fifth straight quarter of double-digit gains. Airway clearance revenue from AffloVest dropped 25% to $10.0 million, which management linked to dealers managing inventory ahead of a next-generation product rollout. I also checked this using Tickeron’s AI Screener to compare performance against other medical device names.
GAAP net income fell to $7.2 million, or $0.31 per diluted share, from $8.2 million, or $0.36 per diluted share, a year ago. Operating income slipped to $9.6 million from $11.0 million as operating expenses climbed 13% to $60.9 million. Gross margin improved to 76.7% from 75.8%, and adjusted EBITDA remained essentially flat at $14.3 million, a touch above estimates.
Market Reaction and Sentiment
Shares declined about 8% in after-hours trading as investors balanced the revenue growth against lower profits stemming from higher operating costs. The split between product lines shaped the response: lymphedema continues to perform well, yet expenses are rising roughly in line with revenue, which tempers bottom-line benefits. The improved adjusted EBITDA guidance did not fully offset worries about softer profit growth in the fourth quarter. Optimism before the release made the modest revenue shortfall and cost trends stand out as near-term concerns.
Forward Outlook and Factors to Watch
Management held full-year 2026 revenue guidance at $360 million to $366 million, implying 9% to 11% growth, while lifting adjusted EBITDA expectations to $50 million to $52 million from the prior $49 million to $51 million range. One area to monitor is how quickly the airway clearance transition stabilizes, as exact timing for inventory resets has not been detailed. Expense management remains key, with sales, marketing, reimbursement, and administrative costs outpacing revenue so far. Gross margin gains, now in their 12th straight quarter, should help offset some of that pressure. Additional items include payer mix trends, new product uptake, and any further capital allocation moves after recent share repurchases.
Using AI Tools in My Research Process
When reviewing earnings like these, I often turn to Tickeron’s AI Screener to quickly filter peers by fundamentals, technical patterns, and sector trends. It helps surface comparable setups across medical devices without manual effort, which is useful when assessing whether TCMD’s growth profile stands out. The platform’s customizable criteria make it straightforward to benchmark revenue momentum and margin trends against the broader group.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TCMD in upward trend: 10-day moving average crossed above 50-day moving average on October 22, 2026
The 10-day moving average for TCMD crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on TCMD as a result. In 77 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
TCMD moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where TCMD advanced for three days, in 210 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 197 of 234 cases where TCMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 62 cases where TCMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
TCMD broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. TCMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.314) is normal, around the industry mean (4.204). P/E Ratio (20.982) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (1.458) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical devices developer
Industry MedicalNursingServices
Advertisement